The future of the global interventional cardiology & peripheral vascular device market looks promising with opportunities in the hospital and ambulatory surgical center markets.
- Within the type category, interventional cardiology devices is expected to witness higher growth over the forecast period due to increasing minimally invasive cardiac procedures adoption.
- Within the end use category, hospitals is expected to witness higher growth over the forecast period due to rising demand hospital based advanced cardiac treatment.
- In terms of regions, North America is expected to witness the highest growth over the forecast period due to growing advanced healthcare infrastructure and procedure uptake.
Emerging Trends in Interventional Cardiology & Peripheral Vascular Device Market
Three Major Trends Will Drive The Interventional Cardiology & Peripheral Vascular Device Market Through 2027: Integration of clinical endpoints into device procedures, hospital demand for safe devices with strong clinical evidence, and the shifting focus of manufacturing teams toward high-risk, hard-to-treat patient anatomies.- Minimally Invasive Treatment: TAVR programs and other trans-catheter platforms continue expanding and replacing select open-heart procedures. Wider clinical evidence support and lower-limit risk patient groups will drive clinical trials focused on measuring how quickly patients recover after treatment, as opposed to just their mortality rates. Lower-profile delivery systems will be necessary to address the increasing patient populations.
- Device Convergence: The trend of integrating delivery systems, imaging, therapy and drug-elution within a single system continues; as does the adoption of intravascular imaging systems. Boston Scientific reported expected 2024 cardiovascular revenue of approximately $10.1 billion. Further integration of these systems within cardiovascular platforms will be key to purchase decisions.
- Digital and Automated Systems: Integration of AI, digital and robotic systems to assist, guide and further automate procedures continue moving beyond pilot stage toward limited clinical use. Hospitals continue evaluation and purchase of software that enables real time sizing and positioning, further aiding procedure planning and reducing radiation dose. Digital and automated systems will favor purchase of systems that consistently improve clinical outcomes.
- Peripheral Disease Expansion: Rising cases of diabetes and obesity, as well as the aging population, result in increased prevalence of peripheral artery disease (PAD). The American Heart Association estimates that over 8.5 million U.S. adults are affected. PAD treatment and screening are becoming more common, and patients are seeking outpatient treatments. Therefore, there will be a greater need for atherectomy and thrombectomy devices as well as drug-coated technologies.
- Supply Chain Management: After disruptions to the supply chain caused by the pandemic, companies are qualifying regional manufacturing and dual-sourcing of nitinol, polymers, balloons, and other components. Procurement contracts signed through 2025 will focus on inventory visibility and domestic capacity. This will create challenges for companies and impact their margins and hospital contracts for the next 10 years. Clinical proof is as important as engineering in determining market access.
Recent Developments in the Interventional Cardiology & Peripheral Vascular Device Market
We expect accelerating interventional cardiology and peripheral vascular device activity through 2025-2027 as hospitals prioritize minimally invasive, outpatient treatment pathways, and differentiated clinical outcomes. While we believe the strongest growth will be in structural heart and drug-coated and other imaging-enabled technologies, we expect the reimbursement and evidence environment to continue to influence purchasing decisions.- Structural-heart Approvals: Abbott’s February 2025 FDA approval of its Tri Clip G4 device to repair tricuspid regurgitation (with a previous approval to repair mitral regurgitation) expanded edge-to-edge repair to another underserved indication, and is expected to increase referrals, specialization, and device investments in the next three to five years.
- Robotic Intervention: Siemens Healthineers’ enhancements to its CorPath GRX system in 2025 to support robotic intervention in peripheral vascular disease further extended the company’s leadership in robotic systems. While cost may inhibit some adoption, the potential for improved procedure outcomes and reduced exposure to radiation may be compelling to higher volume centers.
- Peripheral Drug Delivery: Cordis, a subsidiary of Johnson & Johnson, expanded the commercialization of its SELUTION SLR drug-coated balloon in 2025 for the treatment of peripheral arterial disease. While drug-coated balloons have existed to treat peripheral arterial disease, SELUTION SLR employs a unique, sustained-release delivery system of sirolimus to improve outcomes and reduce restenosis.
- Strategic Portfolio Expansion: With its cardiovascular businesses providing strong revenue in 2024, Boston Scientific continued to acquire and/or invest in product development, creating an even stronger portfolio and increased switching costs for hospital customers.
- Outpatient Migration: U.S. ambulatory surgery centers performed more cardiovascular procedures during 2025, as same-day discharge protocols expanded. Expect this trend to favor compact and versatile systems, with the additional advantage of lower costs for consumables, and purchasing decisions to shift from inpatient hospital committees to integrated physician networks.
Strategic Growth Opportunities in the Interventional Cardiology & Peripheral Vascular Device Market
The interventional cardiology and peripheral vascular device markets are forecasted to undergo a broad-based replacement and access cycle from 2024 to 2026, in Lucintel’s market assessment. Mounting an aging population, increased diagnosis and outpatient procedures, and shorten hospital stay creates shifting demand. Consequently, the device markets are shifting value toward differentiated devices and better procedure economics, as opposed to the more traditional focus on volume.- New Cardiovascular Indications: Continued advances are changing the cardiovascular device market. FDA approval of the first transcatheter tricuspid valve replacement in Feb 2025 expanded the field of indications for valve replacements. Other first-in-class interventions for chronic total occlusion and below the knee PAD are among the advancements extending the device market beyond traditional coronary interventions.
- Premium Precision Devices: Other advancements in devices command a higher premium in the marketplace and can improve overall clinical outcomes. Devices incorporating drug-coated elements and other distal delivery systems can improve clinical and procedural outcomes. In Jan 2025, Boston Scientific reported strong sales and positive market momentum in their cardiovascular devices.
- Increased Ambulatory Care: Combined with advancements in drug eluting and other stents, as well as simplified peripheral closures and access devices, processes and procedures can be shifted from inpatient to outpatient care. In Mar 2025, 20 additional outpatient procedures became eligible for reimbursement at ambulatory surgical centers.
- Geographic Expansion: Suppliers can serve as first movers for markets with increasing incidences of diabetes, smoking, and cardiovascular disease, but constrained catheterization capacity. The India healthcare budget for 2025-26 allocated about ₹1.06 trillion. Sustained adoption in Asia-Pacific and other markets will be aided by regional partnerships and training.
- Digital Procedural Support: The FDA approved over 1,000 AI-enabled medical devices as of April 2025. In 2025, devices with artificial intelligence (AI) and robotic assistance for procedures to diagnose and treat various conditions gained significant traction. Digital will shape provider preferences toward less-invasive, complication-free procedures that provide better control and increase utilization.
Interventional Cardiology & Peripheral Vascular Device Market Drivers and Challenges
The interventional cardiology and peripheral vascular device market is expected to experience growth due to advancements in technology and the aging population. Other factors expected to drive the market include health care investments and changes in reimbursement policies. There is a focus on minimally invasive procedures, connected devices and individualized treatment. Regulatory scrutiny, price and reimbursement challenges, supply chain and access inequity are expected market constraints. According to Lucintel, safety, speed, and affordability will be the greatest market differentiators as providers seek cost-effective, quicker solutions.The factors responsible for driving this market include:
- Increasing Prevalence of Cardiovascular Diseases: With increased aging of the global population, the prevalence of cardiovascular diseases is also expected to rise, increasing the demand for devices such as stents, balloons, and thrombectomy devices. The World Health Organization (2025) estimates that 17.9 million people die from cardiovascular diseases every year. This underserved need is expected to increase device demand over the next three to five years.
- Shift Toward Less-invasive Procedures: Less invasive surgical procedures result in reduced trauma and hospital stay. According to the American College of Cardiology (2025), same-day discharge pathways for selected percutaneous coronary interventions were on the rise. The focus on minimally invasive procedures will increase demand for faster, more efficient, and less costly devices.
- Driving Forces: Innovations in Drug-coated Balloons, Bioresorbable Devices, Intravascular Imaging, and Artificial Intelligence, coupled with changes to Robotics, and other medical technology platforms, are streamlining assessment and improving treatments of cardiovascular diseases. The U.S. Food and Drug Administration approved more than 1,000 medical devices containing Artificial Intelligence (AI) in February 2025, and other advanced digital technologies, signaling rapid integration in the industry. In the next 3-5 years, major advancements in cardiovascular technology will result in improved clinical outcomes, increased numbers of patients that can be treated, and greater competition to demonstrate superior clinical evidence.
- Obstacles: Reimbursement and Regulatory Barriers: Traditionally, determining regulatory pathways and securing Medicare reimbursement for new cardiovascular technologies has been challenging and time consuming. In January 2025, Centers for Medicare and Medicaid Services (CMS) finalized several rules that are expected to improve and speed up the pathway for Medical Device and Diagnostic code assignment. From a manufacturer’s perspective, creating an evidence base for performance, cost, and durability will continue to be important. From a provider’s perspective, regulatory frameworks and reimbursement pathways will continue to play an important role in anchoring confidence in the cardiovascular technology market.
- Opportunities: Integration of New Technologies in Medicine and Cardiovascular Care: Advances in Technology and materials are allowing the cost-effective production of miniaturized devices that are smaller and have greater functionality. In June 2025, the use of additive manufacturing in production of medical devices expanded to include small, customized components and device prototyping. This will shorten development times and create the ability to produce patient-specific medical devices and devices for a broad array of cardiovascular and peripheral vascular indications.
The challenges facing this market include:
- High Risk and Limitations of Use: Failure of the devices, restenosis, thrombosis, embolization, bleeding, and other complications can create a significant liability and limit adoption. In April 2025, regulators continued to focus on post-market surveillance and the use of real world evidence to evaluate higher-risk medical devices. In the next three to five years, more stringent evidence requirements will increase the cost and duration of clinical studies, and favor companies with long-term clinical data.
- Price Based Competition: Constraints on hospital budgets, staff shortages and pressure to lower procedure costs, create a price based competition for medical devices. In October 2025, the effects of rising costs for healthcare were evident in several national systems. In the next three to five years, device manufacturers will have to demonstrate measurable economic value in their products, reduce production costs and increase flexibility in contracting in order to protect their margins.
The growth of interventional cardiology and peripheral vascular medical device markets will be a result of increasing aging and chronic disease populations; as well as increasing use of less invasive medical procedures and technology. As a result, the number of medical devices used in these procedures will grow. The markets, however, will be constrained as a result of supply chain disruptions and inadequate access to healthcare, especially in lower and middle income countries. Growth will be a result of improvements in manufacturing and ease of clinical use of medical devices as well as measures of improvement in healthcare system outcomes.
List of Interventional Cardiology & Peripheral Vascular Device Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies interventional cardiology & peripheral vascular device market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the interventional cardiology & peripheral vascular device market companies profiled in this report include:
- Abbott Laboratories
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- Medtronic Public Limited Company
- C. R. Bard, Inc.
- Cook Medical Inc.
- Terumo Corporation
Interventional Cardiology & Peripheral Vascular Device Market by Segment
The study includes a forecast for the global interventional cardiology & peripheral vascular device market by type, device, end use, and region.Type [Value ($M) from 2019 to 2035]:
- Interventional Cardiology Devices
- Peripheral Vascular Devices
Device [Value ($M) from 2019 to 2035]:
- Angioplasty Balloons
- Angioplasty Stents
- Angioplasty Catheters
- EVAR Stent Graft
- IVC Filter
- Embolic Protection Devices
- Guidewires
- Arteriotomy Closure Devices
- Intravascular Ultrasound System
- Synthetic Surgical Graft
End Use [Value ($M) from 2019 to 2035]:
- Hospitals
- Ambulatory Surgical Centers
Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Interventional Cardiology & Peripheral Vascular Device Market
According to Lucintel’s most recent research, through 2025-2027, investments by hospitals, location of manufacturing, local reimbursement, and regulatory approvals will be the driving forces behind developments in the Interventional Cardiology and Peripheral Vascular Devices markets. Although no independent forecasts are provided, these market drivers will impact supplier strategies, and reinforce customer preference patterns.- United States: FDA clearances and hospital investment programs will increase adoption of medical devices, thus reinforcing the shift towards technology-enabled cardiovascular procedures. The FDA’s approval in February 2025 of expanded labeling for Medtronic’s Pulse Select Pulsed-Field Ablation System will also reinforce similar trends.
- China: Local production and regulatory localization will continue to be key foci; the 2025 target set by the State Council requires that China’s total output of medical devices reach 1 trillion RMB; in 2025, the NMPA approved a series of cardiovascular medical devices, including coronary stents, drug-coated balloons, and thrombectomy systems. These will promote local supplier participation and shift global manufacturer/partnership strategies.
- Germany: Public investment in Germany’s hospital modernization program provides up to €50 billion. Siemens Healthineers will continue to build out their advanced therapy and imaging manufacturing businesses. Demand for integrated catheterization lab equipment, and locally serviced devices, will be supported by this funding.
- India: In 2022, the government’s ‘Make in India’ policy was formalized with the implementation of the Production Linked Incentive (PLI) scheme. It allocated ₹3,420 crore for the Medical Devices sector for the period 2022-27. Meril Infrastructure increased their domestic production of Cardiovascular Implant devices. These should support the localization of stents, valves, and other delivery systems and reduce dependence on imports.
- Japan: With little impact from the FY2025 medical-fee revisions, which increased the overall medical service fee by 0.19% in April 2025, and continued investment in R&D by Japanese device manufacturers, the economics for cardiovascular procedures in Japan should improve and further anchor Japanese device manufacturers in sophisticated catheter technology.
Features of the Global Interventional Cardiology & Peripheral Vascular Device Market
- Market Size Estimates: Interventional cardiology & peripheral vascular device market size estimation in terms of value ($M).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: Interventional cardiology & peripheral vascular device market size by type, device, end use, and region in terms of value ($M).
- Regional Analysis: Interventional cardiology & peripheral vascular device market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, device, end use, and regions for the interventional cardiology & peripheral vascular device market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the interventional cardiology & peripheral vascular device market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the interventional cardiology & peripheral vascular device market by type (interventional cardiology devices and peripheral vascular devices), device (angioplasty balloons, angioplasty stents, angioplasty catheters, EVAR stent graft, IVC filter, embolic protection devices, guidewires, arteriotomy closure devices, intravascular ultrasound system, and synthetic surgical graft), end use (hospitals and ambulatory surgical centers), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Abbott Laboratories
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- Medtronic Public Limited Company
- C. R. Bard, Inc.
- Cook Medical Inc.
- Terumo Corporation
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

